HI SB1531

Establishes the Beneficial Treatments Advisory Council within the Department of Health to review and evaluate mental health treatment options, with specific focus on psilocybin, psilocybin-based products, and methylenedioxymethamphetamine (MDMA).

Council membership consists of 5 ex officio voting members (executive director of the Office of Wellness and Resilience as chairperson, attorney general, senate and house health committee chairpersons, and state council on mental health chairperson) plus 4 appointed members including physicians, substance abuse/psychiatry specialists, and representatives from psychedelic advocacy organizations and research institutions.

Council shall examine federal, state, and local laws regarding mental health treatment; review medical and scientific studies on safety and efficacy of treatment methods; examine professional requirements in jurisdictions using these treatments; and develop a long-term strategic plan for availability of therapeutic psilocybin and MDMA for adults 21 years and older.

Council members serve without compensation but receive reimbursement for expenses including travel necessary for performance of duties.

Act takes effect on December 31, 2050.